KZA 0.00% 8.0¢ kazia therapeutics limited

Ann: Kazia releases final data from P2 paxalisib trial, page-56

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 114 Posts.
    lightbulb Created with Sketch. 125
    This free article provides a good summary of further disease targets for a brain penetrant PI3K/mTOR inhibitor like paxalisib (see last point of tinhat‘s post above):

    https://dx.doi.org/10.3390%2Fijms20225792
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.